Bleichmar Fonti & Auld LLP (BFA) announced a lawsuit against RxSight, Inc. (NASDAQ: RXST) and several senior executives. The lawsuit, filed in the U.S. District Court for the Central District of California, alleges violations of federal securities laws. The case, Makaveev v. RxSight, Inc., et al., claims the company made misleading statements regarding the sales and adoption of its products.
RxSight manufactures and sells adjustable intraocular lenses used in cataract surgery, along with related equipment. Their primary product, the Light Adjustable Lens (LAL), can be customized post-surgery using a Light Delivery Device (LDD). The complaint contends that RxSight, during a specified period, promoted strong sales figures without disclosing significant challenges in LAL adoption.
The lawsuit highlights two instances where RxSight revised its revenue forecasts downward. In April 2025, the company lowered its full-year revenue projection, citing market softening that had begun in the latter half of 2024. This announcement resulted in a significant drop in RxSight‘s stock price. A similar event occurred in July 2025, with another revenue forecast reduction and corresponding stock price decline, attributed to persistent challenges in LAL adoption.
BFA argues that these downward revisions reveal RxSight‘s prior statements were inaccurate and misleading to investors. The firm represents investors who purchased RxSight securities during the relevant period. The firm is seeking to represent a class of investors who suffered financial losses due to the alleged misrepresentations.
Investors who purchased RxSight securities have until September 22, 2025, to petition the court for appointment as lead plaintiff. BFA is handling the case on a contingency fee basis, meaning there are no upfront costs for investors. The firm will seek cour
Related
